3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Rectal Neoplasms
18
Colorectal Neoplasms
17
Stomach Neoplasms
10
Colonic Neoplasms
7
Gastrointestinal Neoplasms
2
Adenocarcinoma
2
Turcot syndrome
1
Recurrence
1
Rcctal Cancer
1
Neoplasms
1
Neoplasm Metastasis
1
Locally Advanced Rectal Cancer (LARC)
1
Locally Advanced Rectal Cancer
1
Locally Advanced Gastric Cancer
1
Locally Advanced Colorectal Cancer
1
Intestinal Neoplasms
1
HER2-positive Locally Advanced Resectable Gastric Cancer
1
HER2-positive Colorectal Cancer
1
Gastrointestinal Diseases
1
Gastric Adenocarcinoma
1
Digestive System Diseases
1
Carcinoma
1
Adebrelimab (SHR-1316)
1
Interventions
Nivolumab
5
pembrolizumab
3
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
durvalumab
2
atezolizumab
2
Celecoxib
2
spartalizumab
1
relatlimab
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
danvatirsen
1
XELOX
1
Surgical Procedures, Operative
1
Oxaliplatin
1
Leucovorin
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
IMM-101
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
DEAE-Dextran
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Turcot syndrome
×
XELOX
×
Clear all
NCT07266025
2026-01-27
CATALIS
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
30 enrolled